miR-205 在肾细胞癌中的表达及其与临床病理特征和预后的关系。
Expression of miR-205 in renal cell carcinoma and its association with clinicopathological features and prognosis.
机构信息
Department of Nephrology, Weifang People's Hospital, Weifang, Shandong Province, China.
出版信息
Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):662-670. doi: 10.26355/eurrev_201802_14291.
OBJECTIVE
The aim of the present study was to examine the expression of miR-205 in renal cell carcinoma (RCC) tissue and carcinoma cells; also, we aimed to determine the association of miR-205 expression with the clinicopathological features and prognosis of RCC, and to explore the mechanism of miR-205.
PATIENTS AND METHODS
Carcinoma tissue and adjacent normal tissue were collected from 60 patients with RCC, and the expression of miR-205 was determined by semi-quantitative PCR, followed by correlation analysis of miR-205 with clinicopathological features and prognosis. Subsequently, the human RCC line, ACHN, was transfected with miR-205, and the effect of miR-205 overexpression on the growth of RCC was examined by MTT assay. Moreover, the effect of miR-205 on the migration of colon cancer cells was studied by transwell assay. Additionally, immunohistochemistry and Western blot were used to investigate the epithelial-mesenchymal transition in renal cancer tissue.
RESULTS
The expression of miR-205 was downregulated in RCC tissue compared with adjacent non-cancerous tissue (p < 0.01). The expression of miR-205 was closely related to the infiltration and recurrence of tumors (p < 0.01), but was not correlated with a pathological grade or clinical stage (p > 0.05). We also found that overexpression of miR-205 in RCC significantly inhibited the growth of cancer cells (p < 0.01) and significantly reduced the migration ability (p < 0.01). The epithelial-mesenchymal transition occurs in RCC, and miR-205 might inhibit cell proliferation and migration by blocking the epithelial-mesenchymal transition.
CONCLUSIONS
The expression of miR-205 is low in RCC, and may play an important role throughout the progression of RCC. Further study of miR-205 may promote the development of a novel therapeutic approach for the treatment of RCC.
目的
本研究旨在检测 miR-205 在肾细胞癌（RCC）组织和癌细胞中的表达，并探讨 miR-205 的表达与 RCC 临床病理特征和预后的相关性，同时研究 miR-205 的作用机制。
方法
收集 60 例 RCC 患者的癌组织及癌旁正常组织，采用半定量 PCR 检测 miR-205 的表达情况，对 miR-205 与临床病理特征和预后的相关性进行分析。随后，将 miR-205 转染入人 RCC 细胞系 ACHN，通过 MTT 实验检测 miR-205 过表达对 RCC 生长的影响。通过 Transwell 实验研究 miR-205 对结肠癌细胞迁移的影响。采用免疫组化和 Western blot 检测肾癌细胞上皮间质转化。
结果
与癌旁非癌组织相比，RCC 组织中 miR-205 的表达下调（p<0.01）。miR-205 的表达与肿瘤浸润和复发密切相关（p<0.01），但与病理分级或临床分期无关（p>0.05）。我们还发现，在 RCC 中过表达 miR-205 可显著抑制癌细胞的生长（p<0.01）和迁移能力（p<0.01）。RCC 中发生上皮间质转化，miR-205 可能通过阻断上皮间质转化抑制细胞增殖和迁移。
结论
miR-205 在 RCC 中表达下调，可能在 RCC 的发生发展中发挥重要作用。对 miR-205 的进一步研究可能促进开发治疗 RCC 的新方法。
Zotero 插件